Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by (68) Ga-PSMA-positron emission tomography/computerized tomography.

The first evaluation of pelvic extended lymph node dissection (pLND) in oligometastatic prostate cancer (PCa) detected by (68) Ga-PSMA PET/CT.

Retrospective analysis of 35 PCa patients underwent (68) Ga-PSMA PET/CT affected by biochemical recurrence (BCR) after curative treatment (n = 23) or before primary therapy of high-risk PCa (n = 12).

We performed pLND associated with pathologic imaging in 17 men with nodal oligometastatic PCa.

Indicative lesions for PCa in PET/CT were detected in 91. 4% (32 of 35) of patients. Nodal, bone, visceral (pulmonary), and within the prostate suspected disease were detected in 72% (23 of 32), 16% (5 of 32), 6% (2 of 32), and 47% (15 of 32) of patients, respectively. Median serum PSA in patients with pathological radiotracer uptake in recurrent and high-risk PCa patients was 2. 9 ng/ml (range 0. 18-30) and 19. 5 ng/ml (range 6-90), respectively. The median number of removed lymph nodes with pLND in recurrent and high-risk PCa was 10 (range 4-17) and 12 (range 8-29) per patient and the median number of positive lymph nodes was 1 (range 1-2) and 3 (2-3) per patient, respectively. In total, two false positive and one false-negative lymph node were found. Diagnostic accuracies per nodal lesion in total of 213 removed nodes: sensitivity, 94%; specificity, 99%; positive predictive value (PPV), 89%, and negative predictive value (NPV), 99. 5%. After pLND, 53% (9 of 17) of patients received androgen deprivation therapy and/or radiation therapy and hormonal therapy, while 47% (8 of 17) of patients remained free of any post-surgery therapy. Follow-up PSA remained less than 0. 2 ng/ml in 82% (14 of 17) of patients. After pLND, immediate BCR (PSA never measured less than 0. 2 ng/ml) in 18% (3 of 17) of patients was recorded.

This represents the first study of pLND in the setting of nodal oligometastatic PCa detected by (68) Ga-PSMA PET/CT. The use of (68) Ga-PSMA PET/CT could be to improve the accuracy for the detection of nodal micrometastases. These promising findings need validation in larger studies. Prostate © 2015 Wiley Periodicals, Inc.

The Prostate. 2015 Sep 10 [Epub ahead of print]

S Hijazi, B Meller, C Leitsmann, A Strauss, J Meller, C O Ritter, J Lotz, H-U Schildhaus, L Trojan, C O Sahlmann

Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany. , Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. , Department of Radiology, University Medical Center Goettingen, Goettingen, Germany. , Institute of Pathology, University Medical Center Goettingen, Goettingen, Germany. , Department of Urology, University Medical Center Goettingen, Goettingen, Germany. , Department of Nuclear Medicine, University Medical Center Goettingen, Goettingen, Germany.

PubMed